ISDA

Entry Detail

PDB ID:

4FRK

Keywords:

HYDROLASE/INHIBITOR

Title:

Crystal structure of BACE1 in complex with aminooxazoline xanthene 11a

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2012-06-26

Release Date:

2012-09-12

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.10 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 61 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Beta-secretase 1
Mutations:R(-5)K, R(-4)K
Chain IDs:A
Chain Length:411
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P56817 Pfam ID:PF00026 EC:3.4.23.46

Ligand Molecules

DWD

GOL

IOD

Primary Citation

Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer's Disease.

Huang, H, La, D.S, Cheng, A.C, Whittington, D.A, Patel, V.F, Chen, K, Dineen, T.A, Epstein, O, Graceffa, R, Hickman, D, Kiang, Y.H, Louie, S, Luo, Y, Wahl, R.C, Wen, P.H, Wood, S, Fremeau, R.T.Show

J.Med.Chem. 55 9156 9169 (2012)

PMID: 22928914 DOI: 10.1021/jm300598e

Abstact

A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human β-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound 11a resulted in a significant reduction of CNS Aβ40 in naive rats.

Legend

Protein

Chemical

Disease

Primary Citation of related structures